Ginkgo Bioworks (DNA) reported strong Q3 results driven by $45M in released deferred revenues from the terminated contract with Motif, and cost reduction remains a key priority and is starting to bear fruit, TD Cowen tells investors in a research note. Despite lower Cell Engineering revenue, TD Cowen believes the company’s recent pivot towards providing higher-margin data and AI tools offerings could provide significant opportunities for long-term growth and meaningful, early share capture assuming the market continues its momentum towards AI-enabled drug development. The firm expects a 2025 loss per share of ($6.01) and revenue of $215M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DNA:
- Ginkgo Bioworks Reports Q3 Growth and Strategic Deals
- Closing Bell Movers: Instacart down 6% after earnings
- Ginkgo Bioworks Reports 61% Revenue Jump in Q3 2024
- Gingko Bioworks reports Q3 EPS ($1.08), consensus ($2.72)
- Gingko Bioworks raises FY24 revenue view to $215M-$235M, consensus $185.52M
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
